Harry Heijerman

10.7k total citations · 2 hit papers
145 papers, 5.0k citations indexed

About

Harry Heijerman is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Surgery. According to data from OpenAlex, Harry Heijerman has authored 145 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Pulmonary and Respiratory Medicine, 30 papers in Epidemiology and 18 papers in Surgery. Recurrent topics in Harry Heijerman's work include Cystic Fibrosis Research Advances (123 papers), Neonatal Respiratory Health Research (26 papers) and Inhalation and Respiratory Drug Delivery (24 papers). Harry Heijerman is often cited by papers focused on Cystic Fibrosis Research Advances (123 papers), Neonatal Respiratory Health Research (26 papers) and Inhalation and Respiratory Drug Delivery (24 papers). Harry Heijerman collaborates with scholars based in Netherlands, United States and United Kingdom. Harry Heijerman's co-authors include Daan J. Touw, Gerd Döring, J.S. Elborn, Steven Conway, Henderik W. Frijlink, Patrick A. Flume, Elsbeth M. Westerman, P.P.H. Le Brun, Eitan Kerem and S.P. Conway and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Harry Heijerman

141 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis

2016 401 citations Johanna F. Dekkers, Gitte Berkers et al. profile →
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

2012 365 citations Gerd Döring, Harry Heijerman et al. Journal of Cystic Fibrosis profile →

Peers

Countries citing papers authored by Harry Heijerman

Since Specialization

Citations

This map shows the geographic impact of Harry Heijerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Heijerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Heijerman more than expected).

Fields of papers citing papers by Harry Heijerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Heijerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Heijerman. The network helps show where Harry Heijerman may publish in the future.

Co-authorship network of co-authors of Harry Heijerman

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Heijerman. A scholar is included among the top collaborators of Harry Heijerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Heijerman. Harry Heijerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study 2025 ·JHLT Open ·(unknown), (unknown), Merel E. Hellemons, (unknown), (unknown), Eva Van Braeckel, C. Tji Gan, Hester van der Vaart, Onno W. Akkerman, (unknown), Marieke Verkleij, Harry Heijerman, Erik A.M. Verschuuren	0
2	The Multicenter KOALA Study: The Effects of Kaftrio After Lung Transplantation in Cystic Fibrosis 2024 ·The Journal of Heart and Lung Transplantation ·(unknown), Bart Luijk, Merel E. Hellemons, (unknown), (unknown), Renske van der Meer, C. Tji Gan, C. H. van der Vaart, Onno W. Akkerman, (unknown), Harry Heijerman, Erik A.M. Verschuuren	1
3	Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy 2024 ·BMJ Open Respiratory Research ·Pierre‐Régis Burgel, Manfred Ballmann, Pavel Dřevı́nek, Harry Heijerman, Andreas Jung, Jochen G. Mainz, D. Peckham, Barry J. Plant, C. Schwarz, Giovanni Taccetti, Alan R Smyth	9
4	Validation of the CaReQoL asthma: a patient reported outcome measure for monitoring the perceived effects of pulmonary rehabilitation in adult patients with severe refractory asthma 2023 ·Respiratory Research ·(unknown), Mattanja Triemstra, Bart Knottnerus, (unknown), Harry Heijerman, Dolf de Boer	2
5	Development and validation of a novel personalized electronic patient-reported outcome measure to assess quality of life (Q-LIFE): a prospective observational study in people with Cystic Fibrosis 2023 ·EClinicalMedicine ·Danya Muilwijk, (unknown), (unknown), (unknown), Domenique D. Zomer-van Ommen, Harry Heijerman, Cornelis K. van der Ent	3
6	Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease 2023 ·Pediatric Pulmonology ·(unknown), Firdaus A. A. Mohamed Hoesein, Regina W. Hofland, Inez Bronsveld, (unknown), (unknown), (unknown), (unknown), Cornelis K. van der Ent, Harry Heijerman	6
7	Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation 2022 ·Therapeutic Advances in Respiratory Disease ·(unknown), Tim Takken, (unknown), Sanne L. Nijhof, Cornelis K. van der Ent, Harry Heijerman, (unknown)	0
8	Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF homozygous for the F508DEL mutation 2019 ·Ghent University Academic Bibliography (Ghent University) ·Harry Heijerman, (unknown), D.G. Downey, Marcus Mall, Bonnie W. Ramsey, Steven M. Rowe, (unknown), Eva Van Braeckel, John Welter, Neil Ahluwalia, Gautham Marigowda, (unknown), Samuel M. Moskowitz, (unknown), Patrick R. Sosnay, David S. Goldfarb, Fengjuan Xuan, (unknown), Jennifer L. Taylor‐Cousar, Karen McCoy	2
9	Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations 2019 ·Journal of Cystic Fibrosis ·(unknown), Gitte Berkers, (unknown), Renske van der Meer, Annelotte M. Vonk, Johanna F. Dekkers, (unknown), Sabine Michel, Evelien Kruisselbrink, Rob B.M. de Vries, Hans Clevers, Frank P. Vleggaar, Sjoerd G. Elias, Harry Heijerman, Cornelis K. van der Ent, Jeffrey M. Beekman	38
10	The optimal approach to nutrition and cystic fibrosis 2017 ·Current Opinion in Pulmonary Medicine ·(unknown), Nicole M. de Roos, Harry Heijerman	17
11	The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis 2015 ·Journal of Cystic Fibrosis ·(unknown), (unknown), P.P.H. Le Brun, (unknown), Daan J. Touw, Harry Heijerman	6
12	Proof of principle. Treatment of cystic fibrosis-related diabetes: a possible role for complementary metformin? 2009 ·Journal of Cystic Fibrosis ·J. Merlijn van den Berg, Harry Heijerman	1
13	CFTR Mutations in Turkish and North African Cystic Fibrosis Patients in Europe: Implications for Screening 2008 ·Genetic Testing ·Phillis Lakeman, Gilles Thomas, J.E. Dankert-Roelse, Harry Heijerman, À. Munck, A. Iron, Hartmut Grasemann, Antje Schuster, Martina C. Cornel, Leo P. ten Kate	13
14	Aerosolization of Tobramycin (TOBI ^® ) with the PARI LC PLUS ^® Reusable Nebulizer: Which Compressor to Use? Comparison of the CR60 ^® to the PortaNeb ^® Compressor 2008 ·Journal of Aerosol Medicine and Pulmonary Drug Delivery ·Elsbeth M. Westerman, Anne H. de Boer, Daan J. Touw, P.P.H. Le Brun, Albert C. Roldaan, Henderik W. Frijlink, Harry Heijerman	16
15	Clinical trials in cystic fibrosis 2007 ·Journal of Cystic Fibrosis ·Gerd Döring, J.S. Elborn, Marie Johannesson, Hugo de Jonge, Matthias Griese, Alan R Smyth, Harry Heijerman	36
16	Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands 2007 ·Journal of Cystic Fibrosis ·R.W. Brimicombe, Lenie Dijkshoorn, T. J. K. van der Reijden, (unknown), Tyrone L. Pitt, P.J. van den Broek, Harry Heijerman	26
17	Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus 2000 ·European Respiratory Journal ·Gerd Döring, S.P. Conway, Harry Heijerman, M.E. Hodson, Niels Høiby, Alan R Smyth, Daan J. Touw	463
18	Can Tobramycin Inhalation Be Improved With a Jet Nebulizer? 1999 ·Therapeutic Drug Monitoring ·P.P.H. Le Brun, Alexander A. Vinks, Daan J. Touw, (unknown), Gregor P.M. Mannes, R.W. Brimicombe, Henderik W. Frijlink, Harry Heijerman	20
19	Low-Dose versus High-Dose Ursodeoxycholic Acid in Cystic Fibrosis-Related Cholestatic Liver Disease Results of a Randomized Study with 1-Year Follow-up 1997 ·Scandinavian Journal of Gastroenterology ·Paul C. van de Meeberg, Roderick H.J. Houwen, M. Sinaasappel, Harry Heijerman, (unknown), G. P. Vanberge-Henegouwen	43
20	Creatinine Clearance as Predictor of Tobramycin Elimination in Adult Patients with Cystic Fibrosis 1996 ·Therapeutic Drug Monitoring ·Daan J. Touw, Alexander A. Vinks, F. Jacobs, Harry Heijerman, W Bakker	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact